12 Feb 2009 05:00 AM
PREZISTA(R) Now Available For Pediatric Patients Six Years Of Age And Older As Part Of HIV Combination Therapy
Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., announced the availability of a lower-dose (75 mg) formulation of PREZISTA (darunavir) for pediatric patients with HIV. The announcement follows the FDA approval of PREZISTA, co-administered with ritonavir (PREZISTA/r) and with other antiretroviral agents, for the treatment of HIV infection in pediatric patients six years of age and older, granted December 18, 2008. PREZISTA was developed by Tibotec Pharmaceuticals, Ltd. and is marketed in the U.S. by Tibotec Therapeutics…
